Resources

  • Statement

    Incubate Statement on WTO Decision to Suspend Global IP Rights
    06.30.2022

    The Incubate Coalition issued the following statement preceding the WTO TRIPS Council meeting (July 6-7) and following the World Trade Organization’s decision at its 12th Ministerial Conference in Geneva, Switzerland to waive intellectual property (IP) protections for Covid-19 vaccines.

  • Article

    LTE: Patents protect people’s access to life-saving medicine
    06.05.2022

    See Incubate's letter to the editor about why patents are necessary in protecting patient access.

  • Statement

    Incubate Comment in Response to the FTC’s Request for Comments on the Business Practices of PBMs
    05.25.2022

    Read Incubate's response to the FTC's Solicitation for Public Comments on the Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers 

  • Statement

    Incubate Executive Director John Stanford Statement in Response to the Centers for Medicare & Medicaid Services’ Devastating Final National Coverage Determination for Certain Alzheimer’s Treatments
    04.14.2022

    See Executive Director John Stanford's statement on CMS' Final NCD on Alzheimer's disease and how this will affect the future of biopharmaceutical investment.

  • Statement

    Incubate Letter in Opposition to MA S. 2774
    04.07.2022

    See Incubate's letter to the Massachusetts state legislature in opposition to S. 2774

  • Article

    To Spend Less on Healthcare, Invest in More Medicines
    04.05.2022

    Read John Stanford and JF Formela's op-ed on how we can lower health costs by spending more on drugs.

  • Statement

    Incubate Letter in Opposition to CT SB-13
    03.29.2022

    See Incubate's letter to Connecticut legislature opposing SB-13.

  • Statement

    Gaurav Gupta Comment on the Proposed Decision for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
    02.10.2022

    Incubate Advisory Council member Gaurav Gupta's comment on CMS's Proposed Decision for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

  • Statement

    Incubate Comment on the Proposed Decision Memo for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
    02.10.2022

    Executive Director John Stanford's comment on CMS's Proposed Decision for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

  • Article

    CMS’s Devastating Blow to Seniors
    02.09.2022

    Read Incubate Advisory Council member Gaurav Gupta's op-ed on the CMS's decision to cover Alzheimer's drugs.

  • Statement

    Moonshot Statement
    02.02.2022

    Read Incubate Executive Director John Stanford's statement on President BIden's Moonshot initiative.

  • Article

    Investors Say Drug-Pricing Measure May Shift Incentives for Biotech Venture Funding
    12.02.2021

    A drug-pricing bill the House passed in November could affect which life-sciences startups venture-capital investors are likely to back.